Tumours elicit an immune attack that can stifle their growth, but they can also recruit inflammatory immune cells that suppress this response. A new study identifies distinct immune subtypes of triple-negative breast cancer with two different inflammatory cell types: macrophages or neutrophils. The immune subtype dictates the response to immunotherapy.
This is a preview of subscription content, log in via an institution to check access.
References
Diakos, C. I., Charles, K. A., McMillan, D. C. & Clarke, S. J. Lancet Oncol. 15, e493–e503 (2014).
Galluzzi, L. et al. Oncotarget 5, 12472–12508 (2014).
Kim, I. S. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-019-0373-7 (2019).
Mao, Y. et al. PLoS One 11, e0152500 (2016).
Schmid, P. et al. N. Engl. J. Med. 379, 2108–2121 (2018).
Noy, R. & Pollard, J. W. Immunity 41, 49–61 (2014).
Ethier, J.-L., Desautels, D., Templeton, A., Shah, P. S. & Amir, E. Breast Cancer Res. 19, 2 (2017).
Wellenstein, M. D. et al. Nature https://doi.org/10.1038/s41586-019-1450-6 (2019).
Dongre, A. et al. Cancer Res. 77, 3982–3989 (2017).
Binnewies, M. et al. Nat. Med. 24, 541–550 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests
Rights and permissions
About this article
Cite this article
Maiorino, L., Egeblad, M. Tumours pick the path to cancer inflammation. Nat Cell Biol 21, 1055–1057 (2019). https://doi.org/10.1038/s41556-019-0386-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41556-019-0386-2
- Springer Nature Limited